Ardelyx: IBSRELA Momentum Drives Opportunity [Seeking Alpha]
Ardelyx, Inc. (ARDX)
Last ardelyx, inc. earnings: 3/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ardelyx.com/investor-relations
Company Research
Source: Seeking Alpha
IBSRELA's rapid uptake and projected $410–$430 million 2026 revenue, alongside a patent extension to 2041, create a durable, generational asset and significant terminal value. XPHOZAH's $100M+ annual revenue confirms unmet need in hyperphosphatemia, but its slower growth and reimbursement complexity present ongoing risk to the renal franchise. Pipeline expansion, including a Phase 3 trial for IBSRELA in CIC and next-gen NHE3 inhibitor RDX10531, enhances ARDX's optionality and long-term strategic positioning. frentusha/iStock via Getty Images Ardelyx ( ARDX ) has developed into a commercial execution machine with two FDA-approved, first-in-class medications. Coming into 2026, Ardelyx has a dual-franchise model, which will allow for strong revenue growth while providing a diversified revenue floor. Historically, the nephrology space has This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mention
Show less
Read more
Impact Snapshot
Event Time:
ARDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARDX alerts
High impacting Ardelyx, Inc. news events
Weekly update
A roundup of the hottest topics
ARDX
News
- Ardelyx gains on report Zydus Lifesciences in talks to purchase [Seeking Alpha]Seeking Alpha
- Assessing Ardelyx (ARDX) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- Why The Ardelyx ARDX Story Is Shifting On New Ibsrela Targets And Valuation Assumptions [Yahoo! Finance]Yahoo! Finance
- Ardelyx (NASDAQ:ARDX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Ardelyx (NASDAQ:ARDX) had its "buy" rating reaffirmed by analysts at BTIG Research.MarketBeat
ARDX
Earnings
- 10/30/25 - Beat
ARDX
Sec Filings
- 1/12/26 - Form SCHEDULE
- 1/9/26 - Form 4
- 1/8/26 - Form 144
- ARDX's page on the SEC website